← Takaisin etusivulle

JNJJohnson & Johnson

📅 2026-04-03🇺🇸 S&Phealthcare
243.04 USD
52 viikon vaihteluväli
$141.50
$251.71

AI-konsensus

Mallin arvio
$221.45
Sis. 30 % analyytikkoankkurointi
Ero
-8.9%
Yksimielisyys
0.805/5 mallia
Hajonta
σ 0.08
Analyytikkokonsensus
$241.08(24 analyytikkoa)
AI-yhteenveto
5 viidestä AI-mallia on negatiivisia JNJ. Huomioitavaa: Impact of patent expirations, particularly for key products, could affect rev... AI-konsensusarvio 221.45 8.9% alle nykyhinnan. Mallien yksimielisyys on korkea (0.80). Analyytikkokonsensus: 241.08 (AI -8.1%).
gptclaudegeminideepseekgrokJNJJohnson & J…243.0spot241.1analysts175190205220235250
Pessimistinen (min)
$156.79
-35.5%
Perus (mediaani)
$221.45
-8.9%
Optimistinen (max)
$229.27
-5.7%

Arvion kehitys AI-mallien arviot ja osakkeen hinta ajan yli

Loading...

Mikä muuttui tänään

Konsensusarvio:221.45→221.45(+0.0%)
CAGR
-0.2pp(1 ↓)
MARG
-0.5pp(1 ↓)
no-assumption-changetariff-risk-escalatedmedtech-china-headwind-noted
Mallien erittely
GEMINI
Est.
232.81
Ero
-4.2%
Conf
0.80
DCF 229.27 → Kal. 232.81
Avaintekijät
  • Diversified portfolio across Innovative Medicine and MedTech segments provide…
  • Strong historical profitability and operational efficiency, reflected in high…
  • Global market presence and extensive distribution network contribute to stabl…
Suurin riski
  • Impact of patent expirations, particularly for key products, could affect revenue growth.
  • Regulatory and competitive pressures on drug pricing policies globally, including poten…
  • Successful commercialization of new drugs and technologies from the pipeline is crucial…
Muutos
No material changes to core valuation assumptions from the previous day, reflecting a stable outlook for Johnson & Jo…
Ei muutosta
no change
GPT
Est.
229.30
Ero
-5.7%
Conf
0.80
DCF 224.25 → Kal. 229.30
Avaintekijät
  • Strong product pipeline in oncology and immunology.
  • Investment in MedTech innovation.
  • Stable demand for healthcare products.
Suurin riski
  • Potential patent expirations impacting revenue.
  • Regulatory challenges in drug approvals.
  • Market competition in pharmaceuticals.
Muutos
Assumptions reflect a stable outlook supported by strong fundamentals and a robust product pipeline.
Ei edellistä dataa
stableinvestments
CLAUDE
Est.
221.45
Ero
-8.9%
Conf
0.76
DCF 213.04 → Kal. 221.45
Avaintekijät
  • Historical revenue CAGR of 5.6% (2022–2025) anchors the 5-year forward estima…
  • MedTech segment provides steady mid-single-digit growth from surgical robotic…
  • Trailing EBIT margin of 27.2% reflects strong pricing power and scale; target…
Suurin riski
  • Stelara loss-of-exclusivity (LOE) creates a meaningful revenue headwind in the Innovati…
  • Drug pricing policy risk — Trump administration 100% tariffs on some drug imports could…
  • Pipeline execution risk: oncology and immunology pipeline must deliver regulatory appro…
Muutos
Core assumptions are unchanged from the prior day model. New headlines highlighting 100% tariff risk on drug imports …
Ei muutosta
no-assumption-changetariff-risk-escalatedmedtech-china-headwind-noted
GROK
Est.
218.07
Ero
-10.3%
Conf
0.78
DCF 208.20 → Kal. 218.07
Avaintekijät
  • Historical revenue growth of 5.6% CAGR adjusted to 7% due to strong pipeline …
  • Recent developments highlight strength across key therapeutic areas, supporti…
  • MedTech segment growth driven by advancements in surgical and digital technol…
Suurin riski
  • Potential revenue impact from patent expirations on key drugs like Stelara.
  • Regulatory and pricing pressures in healthcare could compress margins.
  • Intense competition in oncology and immunology therapeutic areas.
Muutos
Assumptions remain consistent with yesterday's model, with no significant changes in key valuation inputs.
Ei muutosta
stable assumptionsminor update
DEEPSEEK
Est.
182.08
Ero
-25.1%
Conf
0.70
DCF 156.79 → Kal. 182.08
Avaintekijät
  • Historical revenue CAGR of 5.6% (2022-2025) provides a baseline for future gr…
  • Analyst consensus projects near-term revenue growth of 9.1% for the next year…
  • Strong trailing EBIT margin of 27.2% demonstrates operational efficiency in t…
Suurin riski
  • Patent expirations, notably for Stelara, create significant revenue headwinds that must…
  • Drug pricing policy pressures could impact margins across the pharmaceutical industry.
  • Pipeline success is uncertain; new drugs may not fully replace lost revenue from loss o…
Muutos
Maintaining consistent assumptions with slight adjustment to revenue growth to reflect near-term analyst expectations…
CAGR
-0.2pp
MARG
-0.5pp
stabilityminor adjustmentconsistency

Arvostusoletukset

CLAUDEDEEPSEEKGEMINIGPTGROK
Liikevaihdon CAGR 5V6.5%4.0%
-0.2pp
7.0%6.0%7.0%
EBIT-marginaalitavoite28.0%25.5%
-0.5pp
28.0%33.0%28.0%
WACC8.2%8.5%8.0%8.5%8.5%
Terminaalikasvu2.0%2.0%2.0%2.0%2.0%

Tunnusluvut

EBIT-marginaali27.2%
EBITDA-marginaali35.9%
ROE32.9%
Nettovelka / EBITDA0.9x
P/E21.9x
EV / EBITDA18.2x
P/B7.2x
Analyytikkojen vaihteluväli– – –

Viimeisimmät uutiset

Trump Slaps 100% Tariffs on Some Drug Imports. What to Know.2026-04-02
Bayer Advances AB-1002 Study, Highlights Pharma Growth Strategy2026-04-02
JNJ Q1 MedTech Preview: Key Drivers and China Headwinds to Watch2026-04-02
Why Johnson & Johnson (JNJ) Is One of the Best Pharma Stocks to Invest in Now2026-04-02
Tilaa sähköpostiuutisetIlmainen · Ei roskapostia · Peruuta milloin vain · Tietosuoja
AI Investor Barometer · 2026-04-03
Kaikki sisältö on tekoälymallien tuottamaa ja voi sisältää virheitä. Tämä on kokeellinen työkalu — ei sijoitusneuvontaa, -tutkimusta eikä -suositusta. Käyttöehdot · Tietosuoja